1
|
Tian Y, Fopiano KA, Patel VS, Feher A, Bagi Z. Role of Caveolae in the Development of Microvascular Dysfunction and Hyperglycemia in Type 2 Diabetes. Front Physiol 2022; 13:825018. [PMID: 35250626 PMCID: PMC8894849 DOI: 10.3389/fphys.2022.825018] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 01/28/2022] [Indexed: 11/13/2022] Open
Abstract
In type 2 diabetes (T2D) microvascular dysfunction can interfere with tissue glucose uptake thereby contributing to the development of hyperglycemia. The cell membrane caveolae orchestrate signaling pathways that include microvascular control of tissue perfusion. In this study, we examined the role of caveolae in the regulation of microvascular vasomotor function under the condition of hyperglycemia in T2D patients and rodent models. Human coronary arterioles were obtained during cardiac surgery from T2D patients, with higher perioperative glucose levels, and from normoglycemic, non-diabetic controls. The coronary arteriole responses to pharmacological agonists bradykinin and acetylcholine were similar in T2D and non-diabetic patients, however, exposure of the isolated arteries to methyl-β-cyclodextrin (mβCD), an agent known to disrupt caveolae, reduced vasodilation to bradykinin selectively in T2D subjects and converted acetylcholine-induced vasoconstriction to dilation similarly in the two groups. Dilation to the vascular smooth muscle acting nitric oxide donor, sodium nitroprusside, was not affected by mβCD in either group. Moreover, mβCD reduced endothelium-dependent arteriolar dilation to a greater extent in hyperglycemic and obese db/db mice than in the non-diabetic controls. Mechanistically, when fed a high-fat diet (HFD), caveolin-1 knockout mice, lacking caveolae, exhibited a significantly reduced endothelium-dependent arteriolar dilation, both ex vivo and in vivo, which was accompanied by significantly higher serum glucose levels, when compared to HFD fed wild type controls. Thus, in T2D arterioles the role of caveolae in regulating endothelium-dependent arteriole dilation is altered, which appears to maintain vasodilation and mitigate the extent of hyperglycemia. While caveolae play a unique role in microvascular vasomotor regulation, under the condition of hyperglycemia arterioles from T2D subjects appear to be more susceptible for caveolae disruption-associated vasomotor dysfunction and impaired glycemic control.
Collapse
Affiliation(s)
- Yanna Tian
- Department of Physiology, Medical College of Georgia, Augusta University, Augusta, GA, United States
| | - Katie Anne Fopiano
- Department of Physiology, Medical College of Georgia, Augusta University, Augusta, GA, United States
| | - Vijay S. Patel
- Department of Surgery, Medical College of Georgia, Augusta University, Augusta, GA, United States
| | - Attila Feher
- Department of Physiology, Medical College of Georgia, Augusta University, Augusta, GA, United States
| | - Zsolt Bagi
- Department of Physiology, Medical College of Georgia, Augusta University, Augusta, GA, United States
| |
Collapse
|
3
|
Thomson SR, Chogtu B, Shetty R, Devasia T. Analysis of glycemic status in diabetes-naïve patients on statins: A hospital-based cross-sectional study. Indian J Pharmacol 2019; 50:320-325. [PMID: 30783324 PMCID: PMC6364334 DOI: 10.4103/ijp.ijp_132_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
INTRODUCTION: Randomized controlled trials, observational studies, and meta-analysis suggest risk of hyperglycemia in patients on statins, and this association is being viewed with renewed interest globally. The present study has tried to explore the possible diabetogenic effect of statins, the mechanism of this effect, and various comorbidities associated with this causation. MATERIALS AND METHODS: This cross-sectional study was carried out at the Department of Cardiology from October 2015 to March 2017. Patients on statins for at least 1 year and normoglycemic at the time of statin initiation were recruited in the study. The outcome of the present study was development of new-onset diabetes mellitus (NODM). Blood glucose levels and insulin levels were estimated. Other adverse reactions of statins and associated comorbidities in the patients were recorded. Descriptive statistics were used to analyze adverse drug reactions. RESULTS: A total of 104 patients met the inclusion criteria, of which eight patients (7.7%) developed NODM and 4 (3.8%) developed prediabetes. Atorvastatin 40 mg was most commonly prescribed statin. About 25% of patients taking atorvastatin 80 mg developed diabetes CONCLUSION: Statins have a mild-to-moderate risk of developing NODM. The dose of statins is an important factor that increases the risk of diabetes in statin users
Collapse
Affiliation(s)
- Sereen Rose Thomson
- Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India
| | - Bharti Chogtu
- Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India
| | - Ranjan Shetty
- Department of Cardiology, Manipal Hospital, Manipal Academy of Higher Education, Manipal, Karnataka, India
| | - Tom Devasia
- Department of Cardiology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India
| |
Collapse
|
4
|
Dou H, Feher A, Davila AC, Romero MJ, Patel VS, Kamath VM, Gooz MB, Rudic RD, Lucas R, Fulton DJ, Weintraub NL, Bagi Z. Role of Adipose Tissue Endothelial ADAM17 in Age-Related Coronary Microvascular Dysfunction. Arterioscler Thromb Vasc Biol 2017; 37:1180-1193. [PMID: 28473444 DOI: 10.1161/atvbaha.117.309430] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2016] [Accepted: 04/12/2017] [Indexed: 12/23/2022]
Abstract
OBJECTIVE A disintegrin and metalloproteinase ADAM17 (tumor necrosis factor-α [TNF]-converting enzyme) regulates soluble TNF levels. We tested the hypothesis that aging-induced activation in adipose tissue (AT)-expressed ADAM17 contributes to the development of remote coronary microvascular dysfunction in obesity. APPROACH AND RESULTS Coronary arterioles (CAs, ≈90 µm) from right atrial appendages and mediastinal AT were examined in patients (aged: 69±11 years, BMI: 30.2±5.6 kg/m2) who underwent open heart surgery. CA and AT were also studied in 6-month and 24-month lean and obese mice fed a normal or high-fat diet. We found that obesity elicited impaired endothelium-dependent CA dilations only in older patients and in aged high-fat diet mice. Transplantation of AT from aged obese, but not from young or aged, mice increased serum cytokine levels, including TNF, and impaired CA dilation in the young recipient mice. In patients and mice, obesity was accompanied by age-related activation of ADAM17, which was attributed to vascular endothelium-expressed ADAM17. Excess, ADAM17-shed TNF from AT arteries in older obese patients was sufficient to impair CA dilation in a bioassay in which the AT artery was serially connected to a CA. Moreover, we found that the increased activity of endothelial ADAM17 is mediated by a diminished inhibitory interaction with caveolin-1, owing to age-related decline in caveolin-1 expression in obese patients and mice or to genetic deletion of caveolin-1. CONCLUSIONS The present study indicates that aging and obesity cooperatively reduce caveolin-1 expression and increase vascular endothelial ADAM17 activity and soluble TNF release in AT, which may contribute to the development of remote coronary microvascular dysfunction in older obese patients.
Collapse
Affiliation(s)
- Huijuan Dou
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - Attila Feher
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - Alec C Davila
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - Maritza J Romero
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - Vijay S Patel
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - Vinayak M Kamath
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - Monika Beck Gooz
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - R Daniel Rudic
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - Rudolf Lucas
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - David J Fulton
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - Neal L Weintraub
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.)
| | - Zsolt Bagi
- From the Vascular Biology Center (H.D., A.F., A.C.D., M.J.R., R.L., D.J.F., N.L.W., Z.B.), Department of Surgery (V.S.P., V.M.K.), Department of Medicine (N.L.W., Z.B.), and Department of Pharmacology and Toxicology (M.J.R., R.D.R., R.L., D.J.F.), Medical College of Georgia, Augusta University; and Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston (M.B.G.).
| |
Collapse
|